Bimekizumab in hidradenitis suppurativa: a valid and effective emerging treatment-Reference-Cited by-同舟云学术

Bimekizumab in hidradenitis suppurativa: a valid and effective emerging treatment

Published:2023-07-05 Issue:11 Volume:48 Page:1272-1274
ISSN:0307-6938
Container-title:Clinical and Experimental Dermatology
language:en
Short-container-title:

Author:

Molinelli Elisa¹,Gambini Daisy¹,Maurizi Andrea¹,De Simoni Edoardo¹^ORCID,Sapigni Claudia¹,Belleggia Sara¹,Rizzetto Giulio¹,Offidani Annamaria¹,Simonetti Oriana¹

Affiliation:

1. Dermatological Unit, Department of Clinical and Molecular Sciences, Polytechnic Marche University , Ancona , Italy

Abstract

Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease in which many inflammatory mediators such as interleukin-17 are involved in the pathophysiology. We describe a rapid improvement in the skin lesions of HS in patients with psoriasis treated with bimekizumab.

Publisher

Oxford University Press (OUP)

Subject

Dermatology

Link

https://academic.oup.com/ced/advance-article-pdf/doi/10.1093/ced/llad229/51202044/llad229.pdf

Reference5 articles.

2. Efficacy of oral zinc and nicotinamide as maintenance therapy for mild/moderate hidradenitis suppurativa: a controlled retrospective clinical study;Molinelli;J Am Acad Dermatol,2020

3. Efficacy and safety of bimekizumab in moderate to severe hidradenitis suppurativa: a phase 2, double-blind, placebo-controlled randomized clinical trial;Glatt;JAMA Dermatol,2021

4. Clinical implementation of biologics and small molecules in the treatment of hidradenitis suppurativa;Aarts;Drugs,2021

5. First-in-human randomized study of bimekizumab, a humanized monoclonal antibody and selective dual inhibitor of IL-17A and IL-17F, in mild psoriasis;Glatt;Br J Clin Pharmacol,2017

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Real‐world effectiveness and safety of bimekizumab for hidradenitis suppurativa: An ambispective observational study;Australasian Journal of Dermatology;2024-06-19

2. Bimekizumab: dual inhibition as a promising tool in the management of hidradenitis suppurativa;The Lancet;2024-06

3. Eligibility in a cohort of patients with hidradenitis suppurativa treated with bimekizumab: Lessons and pitfalls in a real‐world setting;Journal of the European Academy of Dermatology and Venereology;2024-02-27

4. Biologics for Hidradenitis suppurativa: evolution of the treatment paradigm;Expert Review of Clinical Immunology;2023-12-22